RT Journal Article
SR Electronic
T1 Defective neutralizing antibody response to SARS-CoV-2 in vaccinated dialysis patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.05.21264054
DO 10.1101/2021.10.05.21264054
A1 Bassi, Jessica
A1 Giannini, Olivier
A1 Silacci-Fregni, Chiara
A1 Pertusini, Laura
A1 Hitz, Paolo
A1 Terrot, Tatiana
A1 Franzosi, Yves
A1 Muoio, Francesco
A1 Saliba, Christian
A1 Meury, Marcel
A1 Dellota, Exequiel A.
A1 Dillen, Josh
A1 Hernandez, Patrick
A1 Czudnochowski, Nadine
A1 Cameroni, Elisabetta
A1 Beria, Nicola
A1 Ventresca, Mariangela
A1 Badellino, Alberto
A1 Lavorato-Hadjeres, Soraya
A1 Lecchi, Elisabetta
A1 Bonora, Tecla
A1 Mattiolo, Matteo
A1 Trinci, Guido
A1 Garzoni, Daniela
A1 Bonforte, Giuseppe
A1 Forni-Ogna, Valentina
A1 Giunzioni, Davide
A1 Berwert, Lorenzo
A1 Gupta, Ravindra K.
A1 Ferrari, Paolo
A1 Ceschi, Alessandro
A1 Cippà, Pietro
A1 Corti, Davide
A1 Lanzavecchia, Antonio
A1 Piccoli, Luca
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.05.21264054.abstract
AB Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis (HD) and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-naïve HD patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity, consistent with a delayed affinity maturation of SARS-CoV-2 S-specific B cells. These data indicate that dialysis patients should be considered for an additional boost and other therapeutic strategies, including early immunotherapy with monoclonal antibodies.Competing Interest StatementJ.B., C.S.-F., F.M., C.S., M.Me., E.A.D.J., N.C., E.C., D.C. A.L., and L.Pi. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. R.K.G. has received consulting fees from Johnson and Johnson and GlaxoSmithKline. The other authors declare no competing interests.Funding StatementThe project was partially funded by the Swiss Kidney Foundation (to O.G). We acknowledge support from the G2P-UK National Virology consortium funded by MRC/UKRI (grant ref. MR/W005611/1, to R.K.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were obtained from 143 dialysis patients and 48 healthcare workers under study protocols approved by the local Institutional Review Boards (Canton Ticino Ethics Committee, Switzerland). Dialysis patients and HCW were recruited from the four public hospitals of the Ente Ospedaliero Cantonale (EOC) in Ticino (Southern Switzerland). All subjects provided written informed consent for the use of blood and blood components (such as PBMCs, sera or plasma).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. The data that support the findings of this study are available on request from the corresponding author.